Status: Pending
Age: New (14/08/2025)
ICICI Securities Downgrades Biocon to Sell with Target of ₹270
Brokerage
ICICI Securities
Analyst
Brokerage Team
Position
Bearish
Start Date
14/08/2025
Horizon
Long Term
Target Price and Expected Returns
Start Price
₹359.95
Target Price
₹270
Expected Returns
-25.48%
Summary
ICICI Securities has downgraded Biocon to a sell rating with a target price of ₹270, expecting lower margins in the generics division.
ICICI Securities's justification for Biocon target price prediction
- The ICICI Securities report highlighted higher operating costs for new generic facilities.
- Lower-than-anticipated margins in the biologics division were also stated as a concern.
- While Biocon's biologics segment showed strong 18% YoY growth, this was offset by challenges in the generics segment.
- ICICI reduced its EBITDA estimates by 1-2% due to these factors.
- The stock currently trades at a premium relative to the company's valuation.
Sources:
https://www.moneycontrol.com
Tags: